Pasar al contenido principal


Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting

Artículo

Effective Formulation Development Strategies for Poorly Soluble Active Pharmaceutical Ingredients

API solubility character is a critical factor in topical drug development. Unfortunately, most APIs exhibit poor solubility, requiring excipient composition and formulation process adjustments. In addition, 80% of New chemical entities (BCS class II and IV) have a low solubility. The main consequence of insufficient API solubility in the dosage form includes – low drug loading, stability issues, and lower skin permeation.

In the quest for improving the solubility of poorly water-soluble drugs, a host of formulation strategies have been tried by various formulators. These include particle size reduction, crystal engineering, salt formation, use of surfactants, complexation, and so on. One such strategy is incorporating active molecules into microscopic particles (nanoparticles) with highly hydrophilic surfaces. By providing a large surface area in contact with water molecules, they can increase water solubility, which increases their hydrophilicity and facilitates their dissolution.

The three most used solvent systems for rapid and efficient solubilization of poorly water-soluble APIs are Glycols/Polyols, Surfactants/Surface active agents, Poloxamers, or polymers. The effective formulation development strategies for poorly soluble active pharmaceutical ingredients (APIs) are:

Designing an appropriate solvent/co-solvent/solubilizer system

Poorly soluble APIs (APIs) are extremely challenging to formulate, especially in the topical market, due to their low solubility. An appropriate solvent/co-solvent/solubilizer system within a formulation is, therefore, crucial to improving the water-solubility of an API without requiring complex formulation or physicochemical modifications.

Poorly water-soluble active ingredients (APIs) must be solubilized and formulated effectively to enhance their skin permeation and other pharmaceutical properties. For successful drug development, this solubility character is critical and will influence the choice of the excipients and the formulation parameters.

Particle size reduction strategies and crystal engineering

Size reduction strategies by either micronization or nanosizing can enhance a drug's effective surface area (S). In addition, the polymeric stabilizers present within the formulations can improve. Solubility plays a vital role in the drug absorption and dissolution process. Various strategies, such as modification of the structure of the drug, particle size reduction, and crystal engineering, can be explored.

BCS Class II drug product with low solubility and high permeability requires a very fine PSD of the API to match the dissolution profile. Formulators can meet this requirement by offering a micronized API with customized particle sizes. The objective of formulating is to formulate a drug system that can satisfy the following criteria:

  • Pharmaceutical activity or properties are retained or enhanced when administered orally or systemically
  • The physical/chemical form of the drug delivery is compatible with its other desired properties
  • Consumption of active ingredients at therapeutic doses is not significantly harmful because of sub-potent systemic exposure
  • Systemic bioavailability is acceptable
  • Good excipient profile.

Salt Formation Strategies

Salt formation is the most effective process for increasing solubility and dissolution rates for acid and basic drugs. The salt form may well impact the wettability and thereby can increase solubility several hundred-fold, significantly affecting the dissolution rate.

Use of Surfactants

The mechanisms of surfactant solubilization have been substantially evaluated. Therefore, these approaches are attractive as they are aligned with standard tableting processes, easily scalable, and very cost-effective. In addition, surfactants can have several functional roles that include:

  • Enhancing API solubilization, wettability, and dissolution
  • Reducing in-vivo API precipitation

Use of Cyclodextrins

Cyclodextrins are cyclic oligosaccharides used to improve the water-solubility and bioavailability of drugs. They are functional excipients that form dynamic inclusion complexes in solutions with APIs. Typically, the substituted β-cyclodextrins are used in the formulation. Usually, the hydrophobic API resides, and the external hydrophilic cyclic oligosaccharides impart very high aqueous solubility of the complex molecules and typically solubilize APIs as a function of their concentration.

Hydrophilic and Lipidic Solvents

Lipid-based formulations have been shown to enhance oral lipophilic drug absorption and mitigate potential food effects. In addition, drugs with high Log P can be administered efficiently with this approach, as lipidic solvents already fully solubilize the compounds before they enter the body (higher Cs).

Various components of self-emulsifying systems and their selection criteria are reviewed critically, along with attempts made by various scientists to transform liquid self-emulsifying drug delivery systems (SEDDS) into solid SEDDS by adsorption, spray drying, lyophilization, and melt granulation. PEGs, poloxamers, and other hydrophilic vehicles are ideal solvents due to their powerful solvating properties and miscibility with water.

Amorphous Stabilized Approaches

By overcoming crystal lattice energy, amorphous stabilized approaches can increase solubility and yield thermodynamically metastable APIs. These approaches can significantly enhance both solubility and bioavailability.

Contact Us

Rellene el siguiente formulario y nos pondremos en contacto con usted a la brevedad.

Nuestra lienea de contacto email: api@drreddys.com | +91 40 49002253

Renuncia

Ninguna información en este sitio web, incluyendo cualquier referencia a cualquier producto o servicio, constituye una oferta de venta ni se interpretará como tal. Los productos protegidos por patentes válidas no se ofrecen ni suministran para uso comercial. Sin embargo, en ciertos casos, a discreción exclusiva de Dr. Reddy's y sujeto a los requisitos legales locales, las cantidades de investigación de dichos productos pueden ofrecerse para fines de presentaciones regulatorias según la Sección 107A de la Ley de Patentes de la India (exención de Bolar), donde existan dichas exenciones regulatorias. Los compradores deben realizar su propia evaluación del producto o servicio, incluyendo el escenario de patentes en sus respectivos mercados, y serán responsables de todas las responsabilidades relacionadas con las patentes. Dr. Reddy's renuncia a todas las garantías, expresas o implícitas, incluyendo, entre otras, las garantías de comerciabilidad, idoneidad para un propósito particular y no infracción.

Empresa

Contactenos

Follow Us on

  • Twitter

Dr. Reddy’s Laboratories, 8-2-337,
Banjara Hills Rd Number 3,
SBI Executive Enclave, Green Valley,
Banjara Hills, Hyderabad,
Telangana 500034
Phone: 040 4900 2222

© 2025 Dr. Reddy’s Laboratories Ltd. All rights reserved.

Dr. Reddy’s Laboratories, 8-2-337,
Banjara Hills Rd Number 3,
SBI Executive Enclave, Green Valley,
Banjara Hills, Hyderabad,
Telangana 500034
Phone: 040 4900 2222

  • Twitter

© 2025 Dr. Reddy’s Laboratories Ltd.
All rights reserved.

X

Let’s talk API sourcing live at

Tackle sourcing bottlenecks and compliance hurdles

Hall E1 Booth H28 24-26 June 2025, Shanghai

Book a Meeting